These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 34551297)

  • 21. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
    Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
    J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
    Riedel SS; Haladyna JN; Bezzant M; Stevens B; Pollyea DA; Sinha AU; Armstrong SA; Wei Q; Pollock RM; Daigle SR; Jordan CT; Ernst P; Neff T; Bernt KM
    J Clin Invest; 2016 Apr; 126(4):1438-50. PubMed ID: 26927674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation.
    Hu J; Gao Q; Yang Y; Xia J; Zhang W; Chen Y; Zhou Z; Chang L; Hu Y; Zhou H; Liang L; Li X; Long Q; Wang K; Huang A; Tang N
    Theranostics; 2021; 11(2):805-823. PubMed ID: 33391506
    [No Abstract]   [Full Text] [Related]  

  • 24. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
    Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
    Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
    Serio J; Ropa J; Chen W; Mysliwski M; Saha N; Chen L; Wang J; Miao H; Cierpicki T; Grembecka J; Muntean AG
    Oncogene; 2018 Jan; 37(4):450-460. PubMed ID: 28945229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
    Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
    J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H; van Leeuwen F
    Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging roles of DOT1L in leukemia and normal development.
    McLean CM; Karemaker ID; van Leeuwen F
    Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
    Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
    Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
    Krivtsov AV; Feng Z; Lemieux ME; Faber J; Vempati S; Sinha AU; Xia X; Jesneck J; Bracken AP; Silverman LB; Kutok JL; Kung AL; Armstrong SA
    Cancer Cell; 2008 Nov; 14(5):355-68. PubMed ID: 18977325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
    Vlaming H; McLean CM; Korthout T; Alemdehy MF; Hendriks S; Lancini C; Palit S; Klarenbeek S; Kwesi-Maliepaard EM; Molenaar TM; Hoekman L; Schmidlin TT; Altelaar AM; van Welsem T; Dannenberg JH; Jacobs H; van Leeuwen F
    EMBO J; 2019 Jul; 38(14):e101564. PubMed ID: 31304633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
    Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
    Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
    Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
    Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
    Banday S; Farooq Z; Ganai SA; Altaf M
    Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
    Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
    J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
    Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
    Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.
    Roychoudhury J; Clark JP; Gracia-Maldonado G; Unnisa Z; Wunderlich M; Link KA; Dasgupta N; Aronow B; Huang G; Mulloy JC; Kumar AR
    Blood; 2015 Apr; 125(16):2544-52. PubMed ID: 25740828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
    Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.